Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
B.D. Green, P.R. Flatt, C.J. Bailey.
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Diab Vasc Dis Res, 3 (2006), pp. 159-165
[2.]
A. Stonehouse, T. Okerson, D. Kendall, D. Maggs.
Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors.
Curr Diabetes Rev, 4 (2008), pp. 101-109
[3.]
C.F. Deacon.
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Diabetes Obes Metab, 9 (2007), pp. 23-31
[4.]
B. Ahrén.
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Curr Diab Rep, 7 (2007), pp. 340-347
[5.]
S.A. McKennon, R.K. Campbell.
The physiology of incretin hormones and the basis for DPP-4 inhibitors.
Diabetes Educ, 33 (2007), pp. 55-56
[6.]
A.J. Scheen, L.F. Van Gaal.
Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes.
Rev Med Liege, 63 (2008), pp. 105-109
[7.]
Sitagliptin (Januvia) tablets prescribing information. Merck & Co; 2010.
[8.]
Saxagliptin (Onglyza) tablets prescribing information. Bristol-Myers Squibb; 2009.
[9.]
I. Raz, Y. Chen, M. Wu, et al.
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Curr Med Res Opin, 24 (2008), pp. 537-550
[10.]
J.C. Chan, R. Scott, J.C. Arjona Ferreira, et al.
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
Diabetes Obes Metab, 10 (2008), pp. 545-555
[11.]
Exenatide (Byetta) injection prescribing information. Amylin Pharmaceuticals. 2010. http://www.Byetta.com.
[12.]
Lilly. Exenatide once weekly provided superior glucose control compared to BYETTA(R) in DURATION-5 study. http://newsroom.lilly.com/releasedetail.cfmreleaseid=430179.
[13.]
J.B. Buse, J. Rosenstock, G. Sesti, et al.
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Lancet, 374 (2009), pp. 39-47
[14.]
Liraglutide (rDNA origin) injection (Victoza) prescribing information.
Novo Nordisk, (2010),
[15.]
B.D. Green, P.R. Flatt.
Incretin hormone mimetics and analogues in diabetes therapeutics.
Best Pract Res Clin Endocrinol Metab, 21 (2007), pp. 497-516
Copyright © 2011. Lippincott Williams & Wilkins